DAVITA INC. News
DaVita Inc. provides kidney dialysis services for patients suffering from chronic kidney failure in the United States. The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also offers outpatient, hospital inpatient, and home-based hemodialysis services; operates clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers. In addition, the company offers integrated care and disease management services to patients in risk-based and other integrated care arrangements; clinical research programs; physician services; and comprehensive kidney care services. Further, it engages in the provision of acute inpatient dialysis services and related laboratory services; and transplant software business. The company was formerly known as DaVita HealthCare Partners Inc. and changed its name to DaVita Inc. in September 2016. DaVita Inc. was incorporated in 1994 and is headquartered in Denver, Colorado.
see moreDAVITA INC. Market News
12h
DaVita: California Ruling and Q1 EPS Momentum Rise
- A federal appeals court decision striking down California’s dialysis profit cap and a bullish Q1 EPS preview have materially improved DaVita’s near-term outlook. Together these developments reduce regulatory downside and set elevated earnings expectations ahead of the May report.
7d
DaVita DVA: IKC Profitability Fuels Stock Surge Q1
DaVita (DVA) recently reported stronger-than-expected Q4 results and raised 2026 adjusted EPS guidance, while its Integrated Kidney Care (IKC) program reached profitability ahead of schedule—key drivers behind recent stock strength. Persistent cost and reimbursement risks remain the main watch points for investors.
14d
DVA Risks from Medicare Cuts: Investors' Briefing!
Recent CMS scrutiny of dialysis bundled payments has put DaVita (DVA) under renewed pressure. Potential 2–4% Medicare reimbursement reductions, combined with already-muted valuation metrics and mixed analyst signals, create near-term volatility while leaving long-term demand intact. This brief outlines the concrete developments, financial implications, and monitoring priorities for investors.
21d
DaVita Strengthens Position with CKCC Success Now!
DaVita (DVA) reported strong Q4 2025 results and measurable progress in value-based kidney care this quarter, including CKCC quality gains, expanded Integrated Kidney Care participation, and meaningful shared savings—factors boosting investor confidence.
28d
No New Catalysts for DaVita This Week — DVA Calm!!
No material news or sector events affecting DaVita (DVA) emerged in the past week. This article explains the implications for investors, outlines specific catalysts to monitor, and offers practical positioning guidance while the stock trades without fresh drivers.
23 Mar at 04:33
DaVita (DVA) Silent Week: What Investors Need Now.
DaVita saw no material headlines in the past week. While the dialysis provider remains under steady regulatory scrutiny, coping with post-cybersecurity operational impacts, and navigating volume and margin pressures amid heavy buybacks, there were no new events to move the stock. This article summarizes the themes investors should monitor next.
16 Mar at 04:32
DaVita Q4: IKC Gains vs. Dialysis Volume Slump
DaVita (DVA) posted stronger-than-expected Q4 results driven by rapid growth in its Integrated Kidney Care (IKC) programs and international operations, even as traditional dialysis treatment volumes remain a persistent headwind. The earnings beat and strategic shift toward value-based care are shaping investor sentiment and valuation outlooks for the S&P 500 component.